
Our science integrates multi-omics data, network biology, and mechanistic modeling to uncover tumor cell-state dependencies and translate them into selective therapeutic strategies.

The State Engineering Platform combines target discovery, modality design, and biomarker-driven patient selection to deliver tumor-selective therapeutics with higher probability of clinical success.

